Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Eli Lilly (NYSE:LLY) on Tuesday will file lawsuits against two companies that the drug giant is accusing of mass compounding its blockbuster GLP-1/GIP receptor agonist tirzepatide. Tirzepatide is ...

Eli Lilly has linked lepodisiran to sustained reductions in a cardiovascular disease risk factor for nearly 1.5 years, bolstering the company’s argument that the siRNA candidate has an edge over ...

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical company’s weight-loss drug. Hours after Hims & Hers posted a blog ...

Follow Bloomberg India on WhatsApp for exclusive content and analysis on what billionaires, businesses and markets are doing. Sign up here. Eli Lilly and Co. has begun selling its blockbuster ...

Weight loss drugs such as Mounjaro help the body manage blood sugar more effectively, make one feel less hungry, and slow digestion, so the person feels full longer. Mounjaro, chemically known as ...

Showcasing a limited-edition, hand-painted print, the new collection features coordinating styles for kids and adults. By Erin Lassner E-Commerce Writer If you purchase an independently reviewed ...

MNC pharma major Eli Lilly has launched Mounjaro (tirzepatide), a weekly injection for obesity and type 2 diabetes, after obtaining approval from India’s Central Drugs Standard Control ...

The trial results are among the pharmaceutical industry's most critical and closely watched of the year, as they bring Eli Lilly's drug one step closer to becoming a new, needle-free alternative for ...

US-based pharmaceutical giant Eli Lilly has launched its diabetes and weight-loss drug, Mounjaro, in India, following approval from the Central Drugs Standard Control Organisation (CDSCO).

Eli Lilly is developing what could be the first oral GLP-1 agonist. Late-stage clinical trial data is coming this year. The stock has a steep valuation despite trading sideways since the summer.

The much-awaited weightloss and diabetes drug, Mounjaro from US-based Eli Lilly and Company will be ... Mounjaro is indicated along with a reduced-calorie diet and increased physical activity ...